Akero Therapeutics, Inc. (AKRO) has a consensus analyst rating of Buy, based on 14 analysts covering the stock. Of those, 10 recommend buying, 4 recommend holding, and 0 recommend selling.
The analyst consensus price target for AKRO is $46.00, representing a -15.8% downside from the current price of $54.65. Price targets range from a low of $38.00 to a high of $56.00.
